Abstract:AIM To prepare anti-c-Kit monoclonal antibodies and characterize their specificity of epitope recognition. METHODS cDNA encoding human c-Kit extracellular domain was constructed into a procaryotic expression vector pQE30 and the correctness of the reconstructed plasmid pQE30-KitD4-5 was verified by sequencing. The plasmid was transformed into E.coli M15 strain. Recombinant 6 x His pQE30-KitD4-5 was expressed after induction by IPTG for 4 h. Then SDS-PAGE results suggested that the products mainly formed inclusion bodies. The fusion protein was further purified with Ni-NTA-His affinity chromatography and then used to immunize BALB/c mice. The hybridomas were achieved by fusing the immunized spleen cells with the Sp2/0 myeloma cell line. The positive clones were screened by FCM with CHO-hKit cells. Hybidoma clones secreting anti-c-Kit antibodies were further subcloned and investigated for their biological activities by Western blot, rapid isotyping analysis and FCM. RESULTS Recombinant human c-Kit fusion proteins were in vitro expressed and purified to be used as immunogen. One stable hybridoma cell line, which continuously secrets specific anti-c-Kit monoclonal antibody ((SRJ1)) was established. The biological activity studies showed that the monoclonal antibody recognized the natural c-Kit expressed on the Kasumi leukemia cell line, but failed to bind to the normal human peripheral blood cells. Interestingly, this monoclonal antibody failed to recognize a subpopulation of Kasumi cells that is reactive with the commercial anti-c-Kit mAb Ab81 suggesting that the c-Kit expressed by this subpopulation contains some sequencial and/or structural aberrations that are distinguishable by mAb SRJ1. CONCLUSION With an immunization procedure using purified recombinant human c-Kit fusion proteins. a hybridoma cell line continuously and stably secreting anti-c-Kit monoclonal antibody has been established. The monoclonal antibody SRJ1 specifically recognizes human c-Kit expressed on the leukemia cells, and may provide a novel approach to analyze the possible structural variations of c-Kit expressed by different cells.

Generation and application of the NOK/STYK1 monoclonal antibody

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

Preparation and characterization of a novel monoclonal antibody against human PD-1

A Novel Protein Tyrosine Kinase Nok That Shares Homology With Platelet-Derived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis And Metastasis In Nude Mice

[Preparation of Anti-Hnok Antibodies and Expression Examination of NOK in the Lung Cancer Tissues].

Development of a Novel Recombinant Full-Length IgY Monoclonal Antibody against Human Thymidine Kinase 1 for Automatic Chemiluminescence Analysis on a Sandwich Biotin-Streptavidin Platform for Early Tumour Discovery

Preparation and Characterization of Monoclonal Antibodies Against Nucleostemin, a Protein That Controls Cell Proliferation in Stem Cells and Cancer Cells

NOK/STYK1 Interacts with GSK-3β and Mediates Ser9 Phosphorylation Through Activated Akt

NOK/STYK1 Promotes the Genesis and Remodeling of Blood and Lymphatic Vessels During Tumor Progression

[Preparation and Characterization of a Monoclonal Antibody Against Human C-Kit].

NOK promotes tumorigenesis through coordinating epidermal growth factor receptor to boost the downstream signaling in breast cancer

Point Mutation at Single Tyrosine Residue of Novel Oncogene Nok Abrogates Tumorigenesis in Nude Mice

Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer

<i>STYK1/NOK</i>—A Potential Radiotherapeutic Target and Biomarker for Gastric Cancer and Cervical Cancer

Impact of STYK1/NOK Gene Transfection on the Migration and Invasion of Lung Adenocarcinoma Cell Line

Preparing Monoclone Antibody of Human Thymidine Kinase

STYK1 mediates NK cell anti-tumor response through regulating CCR2 and trafficking

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Generation and Characterization of Monoclonal Antibody Against Human PIK3IP1

NOK/STYK1 Has a Strong Tendency Towards Forming Aggregates and Colocalises with Epidermal Growth Factor Receptor in Endosomes

Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human NDPK-A